drugset
drugset / Trial / NCT06267183

A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.

NCT06267183 ↗

Phase 0 Recruiting 53 enrolled Shanghai Synvida Biotechnology Co.,Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate safety, tolerability, PK and immunogenicity of SV001 compare to placebo in Chinese healthy adult volunteers.

Timeline

Start
2024-01-12
Primary completion
2026-11-30
Completion
2026-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SV001 Unknown — —

Indications

idiopathic pulmonary fibrosis